PIK3CA and colorectal carcinoma: The PIK3CA H1047R alteration has been implicated in therapy resistance with CRC, specifically regarding a folinic acid, fluorouracil, and oxaliplatin (FOLFOX) treatment, which is frequently used in clinical practice [21].